Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization
| العنوان: | Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization |
|---|---|
| المؤلفون: | Pedro A. Lemos, Patrick W. Serruys, Olivier Varenne, Alfredo E. Rodriguez, Kaare H. Bønaa, Jörg Reifart, Adam de Belder, Alex Abizaid, Christoph Kaiser, Marco Valgimigli, Lorenz Räber, William Wijns, Peter Jüni, Expedito E. Ribeiro, José M. de la Torre Hernández, Tom Wilsgaard, Stephan Windecker, Philip Urban, Goran Stankovic, Manel Sabaté, Arnoud W J van 't Hof, Robert A. Byrne, Wouter Remkes, Raffaele Piccolo, Orestis Efthimiou, Giovanni Esposito |
| المساهمون: | RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), Piccolo, R., Bonaa, K. H., Efthimiou, O., Varenne, O., Urban, P., Kaiser, C., Raber, L., de Belder, A., Remkes, W., Van'T Hof, A. W. J., Stankovic, G., Lemos, P. A., Wilsgaard, T., Reifart, J., Rodriguez, A. E., Ribeiro, E. E., Serruys, P. W. J. C., Abizaid, A., Sabate, M., Byrne, R. A., de la Torre Hernandez, J. M., Wijns, W., Esposito, G., Juni, P., Windecker, S., Valgimigli, M. |
| المصدر: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease Journal of the American Heart Association, 10(20):e018828. Wiley Piccolo, Raffaele; Bonaa, Kaare H; Efthimiou, Orestis; Varenne, Olivier; Urban, Philip; Kaiser, Christoph; Räber, Lorenz; de Belder, Adam; Remkes, Wouter; Van't Hof, Arnoud W J; Stankovic, Goran; Lemos, Pedro A; Wilsgaard, Tom; Reifart, Jörg; Rodriguez, Alfredo E; Ribeiro, Expedito E; Serruys, Patrick W J C; Abizaid, Alex; Sabaté, Manel; Byrne, Robert A; ... (2021). Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. Journal of the American Heart Association, 10(20), e018828. American Heart Association 10.1161/JAHA.120.018828 <http://dx.doi.org/10.1161/JAHA.120.018828Test> |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_treatment, Myocardial Infarction, Coronary Artery Disease, 030204 cardiovascular system & hematology, DISEASE, left anterior descending artery, 0302 clinical medicine, Risk Factors, drug‐eluting stent, Stent, Bare metal, 030212 general & internal medicine, Original Research, media_common, OUTCOMES, Metal, Drug-Eluting Stents, Interventional Cardiology, 3. Good health, Death, Treatment Outcome, medicine.anatomical_structure, Metals, Drug-eluting stent, bare-metal stents, cardiovascular system, Cardiology, Stents, Cardiology and Cardiovascular Medicine, Human, Artery, Drug, medicine.medical_specialty, media_common.quotation_subject, 610 Medicine & health, Prosthesis Design, Revascularization, 03 medical and health sciences, 360 Social problems & social services, Internal medicine, drug-eluting stent, medicine, Humans, cardiovascular diseases, Left main disease, LESIONS, business.industry, Risk Factor, percutaneous coronary intervention, Bare-metal stent, Percutaneous coronary intervention, left main disease, bare‐metal stents, IMPLANTATION, BIODEGRADABLE-POLYMER, business, BLIND |
| الوصف: | Background New‐generation drug‐eluting stents (DES) reduce target‐vessel revascularization compared with bare‐metal stents (BMS), and recent data suggest that DES have the potential to decrease the risk of myocardial infarction and cardiovascular mortality. We evaluated the treatment effect of DES versus BMS according to the target artery (left anterior descending [LAD] and/or left main [LM] versus other territories [no‐LAD/LM]). Methods and Results The Coronary Stent Trialist (CST) Collaboration gathered individual patient data of randomized trials of DES versus BMS for the treatment of coronary artery disease. The primary outcome was the composite of cardiac death or myocardial infarction. Hazard ratios (HRs) with 95% CIs were derived from a 1‐stage individual patient data meta‐analysis. We included 26 024 patients across 19 trials: 13 650 (52.4%) in the LAD/LM and 12 373 (47.6%) in the no‐LAD/LM group. At 6‐year follow‐up, there was strong evidence that the treatment effect of DES versus BMS depended on the target vessel ( P ‐interaction=0.024). Compared with BMS, DES reduced the risk of cardiac death or myocardial infarction to a greater extent in the LAD/LM (HR, 0.76; 95% CI, 0.68–0.85) than in the no‐LAD/LM territories (HR, 0.93; 95% CI, 0.83–1.05). This benefit was driven by a lower risk of cardiac death (HR, 0.83; 95% CI, 0.70–0.98) and myocardial infarction (HR, 0.74; 95% CI, 0.65–0.85) in patients with LAD/LM disease randomized to DES. An interaction ( P =0.004) was also found for all‐cause mortality with patients with LAD/LM disease deriving benefit from DES (HR, 0.86; 95% CI, 0.76–0.97). Conclusions As compared with BMS, new‐generation DES were associated with sustained reduction in the composite of cardiac death or myocardial infarction if used for the treatment of LAD or left main coronary stenoses. Registration URL: https://www.crd.york.ac.uk/PROSPEROTest ; Unique identifier: CRD42017060520. |
| وصف الملف: | application/pdf |
| تدمد: | 2047-9980 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::009ab3b6a500fb49fbf626d339db320cTest https://doi.org/10.1161/jaha.120.018828Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....009ab3b6a500fb49fbf626d339db320c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20479980 |
|---|